AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback